Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
May 08 2018 - 4:15PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) announced today at
its annual and special shareholders’ meeting held on May 8, 2018,
that the individuals noted below were elected as directors of the
Company. The report on proxies provided by the Company’s transfer
agent indicated the following:
|
|
|
|
|
Name of Nominee |
Votes For |
% |
Votes Withheld |
% |
Michael Cardiff |
1,180,130 |
61.71 |
% |
732,290 |
38.29 |
% |
Carolyn Egbert |
1,193,127 |
62.39 |
% |
719,293 |
37.61 |
% |
Juergen Ernst |
1,195,630 |
62.52 |
% |
716,790 |
37.48 |
% |
Gérard Limoges |
1,184,723 |
61.95 |
% |
727,697 |
38.05 |
% |
Brent Norton |
1,408,042 |
73.63 |
% |
504,378 |
26.37 |
% |
Jonathan Pollack |
1,420,246 |
74.26 |
% |
492,174 |
25.74 |
% |
Robin Smith Hoke |
1,557,585 |
81.45 |
% |
354,835 |
18.55 |
% |
|
|
|
|
|
|
|
New Members of the Board of Directors
Dr. Brent Norton
Dr. Norton is a business leader in the life
science industry with operational and director experience across
several successful enterprises which have achieved significant
product sales and returns for investors. He uses his cross
functional knowledge to develop strategy, raise capital and build
important relationships in the academic and business community. Dr.
Norton founded PreMD, completing IPO’s and listings on both the
Toronto Stock Exchange and the American Stock Exchange.
Operationally, he has research and development and commercial
operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal,
Parke Davis/Pfizer, etc., and taken products through the FDA to
global out-licensing with Johnson & Johnson. He is a founding
Director of Novadaq Technologies (TSX:NDQ) (NASDAQ:NVDQ) and was
recently sold to Stryker Corporation. Dr. Norton has been an active
member of several boards in Canada and the United States. He is a
Venture Partner at Lumira Capital, Executive Chairman & CEO of
Ortho RTI, a member of the Research Committee for CAMH, an Advisory
BOD member for the Ivey International Centre for Health Innovation,
a Director of Alpine Ontario and Past-President and Director of the
Osler Bluff Ski Club.
Jonathan Pollack
Jonathan Pollack is the President of The JMP
Group, a private investment and consulting firm. He is also a
director of several public and private companies including CECO
Environmental Corp. (NASDAQ:CECE). Mr. Pollack also served as
a director of API Technologies Corp., Pinetree Capital Ltd.,
Hanfeng Evergreen Inc. and Lifebank Corp. Previously, he served as
Executive Vice President of API Technologies Corp., a leading
provider of RF/microwave, microelectronics and security
technologies for critical and high-reliability applications from
2009 and as a director from 2007 until January 2011 when it was
sold. From March 2005 through its sale in 2009, he served as
the Chief Financial Officer and Corporate Secretary of Kaboose Inc.
Prior thereto, he worked in investment banking in New York. Mr.
Pollack received a Master of Science in Finance from the London
School of Economics and a Bachelor of Commerce from McGill
University. He sits on the boards of several philanthropic
organizations including the Mt. Sinai Hospital Foundation, the
Crescent School Foundation, and the Sterling Hall School
Foundation.
Robin Smith Hoke
Robin Smith Hoke is a business and legal
executive with over 25 years of healthcare and pharmaceutical
experience in various legal and business roles where she focused on
operations, strategy, business development, acquisitions, strategic
relationships, and commercialization. Ms. Hoke currently serves as
President & CEO of Leiters, a 503B FDA registered outsourcing
service provider with manufacturing facilities in Denver, Colorado
and San Jose, California. She also serves as a member of the Board
of Directors of Camargo Pharmaceutical Services, LLC., a privately
held 505(b)(2) global drug development and regulatory services
company in Cincinnati, Ohio. She previously served as a member of
the board of Oncobiologics, Inc., a publically held clinical stage
biopharmaceutical company focused on identifying, developing,
manufacturing and commercializing complex biosimilar therapeutics.
She previously served as chair of the Board of Directors and
interim chief executive officer at Ricerca Biosciences, LLC, a
pre-clinical CRO. Prior to Ricerca, Ms. Hoke served as the
president of GeneraMedix, Inc., a specialty generic injectable
company and held senior legal and business roles at Cardinal
Health, Inc. She also spent time with Abbott Laboratories, Inc.,
and served as a partner in the business law firm of Kegler, Brown,
Hill & Ritter, Co., L.P.A.
The Company reports the re-appointment of
PricewaterhouseCoopers LLP as the Company's independent
auditor.
The Company’s shareholders approved the adoption
of the 2018 long-term incentive plan. The Company is an “Eligible
Interlisted Issuer” as such term is defined in the TSX Company
Manual. As an Eligible Interlisted Issuer, the Company has relied
on an exemption pursuant to Section 602.1 of the Manual from
Section 613 of the TSX Company Manual, the effect of which is that,
subject to the satisfaction of certain conditions prescribed by the
TSX, the Company will not have to comply with certain Canadian
requirements in connection with the 2018 long-term incentive
plan.
For full voting details please see the voting
results of Aeterna Zentaris Inc. as filed on SEDAR at www.sedar.com
and EDGAR at www.sec.gov.
About Aeterna Zentaris
Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company focused on developing and
commercializing, principally through out-licensing arrangements,
Macrilen™ (macimorelin), an orally available ghrelin agonist, to be
used in the diagnosis of patients with adult growth hormone
deficiency (AGHD). On January 17, 2018, Aeterna Zentaris announced
that that it had, through a wholly-owned subsidiary, entered into a
license and assignment agreement with a wholly-owned subsidiary of
Strongbridge Biopharma plc to carry out development, manufacturing,
registration and commercialization of Macrilen™ (macimorelin) in
the United States and Canada. On December 20, 2017 the Company
announced that the U.S. Food and Drug Administration (FDA) granted
marketing approval for Macrilen™ (macimorelin). On November 27,
2017 Aeterna Zentaris announced that the Marketing Authorization
Application (MAA) for the use of Macrilen™ (macimorelin) for the
evaluation of AGHD was accepted by the European Medicines Agency
(EMA) for regulatory review. For more information, visit
www.zentaris.com.
Contacts:
Aeterna Zentaris Inc.James ClavijoChief
Financial OfficerIR@aezsinc.com843-900-3201
Reilly ConnectSusan
ReillyPresidentsusan.reilly@reillyconnect.com312-600-6783
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024